Chronic Obstructive Pulmonary Disease
Conditions
Keywords
COPD
Brief summary
This study is an observational, multicenter, prospective, single arm study. The objective of this study is to evaluate the safety of Breztri® Aerosphere® in Chinese patients with COPD in real world clinical practice. The study will enrol approximately 3,050 subjects from about 42 sites around China and followed up for 12 weeks.
Detailed description
This study is an observational, multicenter, prospective, single arm study. 3,050 subjects who have been prescribed and have planned to take at least one inhalation of BGF MDI will be enrolled into the study This is an observational study. BGF MDI treatment will be studied through non-interventional approach. It will be carried out under routine clinical practice and the start or end of BGF MDI and other concomitant treatment will be determined by subjects' treating physicians. Eligible subjects will be consecutively enrolled in this study at the time they routinely visit their physician and consent to participate in the study. After enrolled successfully, baseline variables will be collected at V1. Subjects will be followed up every 4 weeks after baseline for a total duration of 12 weeks or until study discontinuation, whichever occurs first. V1 and V2 will be followed up by on-site visit and V3 and V4 will be followed up by telephone call visit. For subjects who remain on study drug throughout the study (i.e., complete 4 Visits), a follow up telephone call will be performed at 14 days after the last visit to collect safety information. For subjects who has an Early Discontinuation, 14 days follow up is needed for AE collecting after the discontinuation. For subjects who had been hospitalized during the first 4 weeks of follow-up due to one or more acute exacerbations of COPD, a follow up telephone call will be performed at 28 days after the last visit to collect safety information. The subjects will be recruited from qualified hospitals. Safety and effectiveness data will be collected following enrollment in the study. Medical records, PROs (COPD Assessment Test \[CAT\], St. George's Respiratory Questionnaire \[SGRQ\], Aerosphere Delivery Technology Metered Dose Inhaler Preference Questionnaire \[AMPQ\], Patient Global Impression of Change \[PGIC\]) will be the data source in this study. Primary endpoint will be the incidence of AEs and SAEs in purpose of monitoring the safety profile of BGF MDI.
Interventions
None listed
Sponsors
AstraZeneca
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Give their signed written informed consent to participate * Age: 18 and above * Chinese, Female or male * Patient with diagnosis of COPD as defined by clinicians * Subjects who have been prescribed and have planned to take at least one inhalation of Budesonide/Glycopyrrolate/Formoterol MDI based on physician's decision.
Exclusion criteria
Subjects who meet any of the following criteria will not be able to enter the study： * Subjects who are currently involved in any other interventional studies. * Drug Allergy: Subjects who have a history of hypersensitivity to formoterol or any other β2-agonists, budesonide or any other corticosteroid components, glycopyrronium or other muscarinic anticholinergics, or any component of the MDI. * Subjects who received investigational drug treatment within 30 days prior to Visit 1.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of all AEs /SAEs | 2022-12-30 | To evaluate the safety profile after BGF MDI treatment in Chinese COPD patients |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline in CAT score | 2022-12-30 | To observe patients' health status after BGF MDI treatment via patient reported outcomes (PROs) |
| Change from baseline in SGRQ score | 2022-12-30 | To observe patients' health status after BGF MDI treatment via patient reported outcomes (PROs) |
| ADT MDI preference questionnaire (AMPQ) | 2022-12-30 | To describe patient preference for the Aerosphere Delivery Technology |
| Patient global impression of change (PGIC) | 2022-12-30 | To observe patients' health status after BGF MDI treatment via patient reported outcomes (PROs) |
| Mean total COPD cost including the direct and indirect COPD cost | 2022-12-30 | To assess total direct and indirect COPD cost |
Countries
China
Outcome results
None listed